Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: A causal relationship?

Journal of Internal Medicine

Volumn 240, Issue 5, 1996, Pages 311-314

  Gustafsson, L L ^a   Eriksson, L S ^a,c   Dahl, M L ^a   Eleborg, L ^a   Ericzon, B G ^a   Nyberg, A ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Peptide Hormones   (Sweden)

Author keywords

Adverse effect; Cyclophosphamide; Debrisoquine; Genotype; Liver failure; Metabolism; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DEBRISOQUINE;

ADULT; ARTICLE; CASE REPORT; DRUG METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029681117     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.42867000.x     Document Type: Article

References (19)

1. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 1991; 20: 194-208.
2. Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3: 588.
3. Bacon AM, Rosenberg S. Cyclophosphamide hepatoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1983; 97: 62-3.
4. Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78: 222-3.
5. Brösen K, Gram LF. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537-43.
6. Kalow W, Bertilsson L. Inter-ethnic factors affecting drug response. In: Testa B, Meyer UA, eds. Advances in Drug Research, Vol. 25. London: Academic Press Ltd, 1994; 1-53.
7. Lennard MS, Tucker GT, Woods HF. Inborn 'errors' of drug metabolism: pharmacokinetic and clinical implications. Clin Pharmacokin 1990; 19: 257-3.
8. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L et al. Genetic analysis of the inter-ethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40: 553-6.
9. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
10. Dahl ML, Johansson I, Porsmyr-Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharm Ther 1992; 51: 12-7.
11. Hadidi AH, Coulter CE, Idle JR. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988; 48: 5167-71.
12. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ et al. Cyclophosphamide metabolism in children. Cancer Res 1995; 55: 803-9.
13. Mizoi Y, Yamamoto K, Ueno Y, Fukunaga T, Harada S. Involvement of genetic polymorphism of alcohol and aldehyde dehydrogenases in individual variation of alcohol metabolism. Alcohol 1994; 29: 707-10.
14. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-32.
15. Swedish Adverse Drug Reaction Committee, Medical Products Agency, data on file 1995.
16. Banks AT, Zimmerman HJ, Ishak KG, Harter JF. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatolog 1995; 22: 820-7.
17. Le Blanc GA, Waxman DJ. Mechanisms of cyclophospamide action in P-450 expression. Cancer Res 1990; 50: 5720-6.
18. Honjo I, Suou T, Hirayama C. Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res Commun Chem Pathol Pharmacol 1988; 61: 149-65.
19. Yokota H, Tomura S, Furuya H, Kimum S, Watanake H, Kanzawa I et al. Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3: 253-63.